Women Show Greater Dementia Risk Reduction From Shingles Vaccine

Why It Matters

If confirmed, the findings could expand the value proposition of the shingles vaccine, positioning it as a preventive tool against neurodegeneration and influencing vaccination strategies for older adults, especially women.

Key Takeaways

• 51% dementia risk reduction after two-dose Shingrix series.
• Women experienced greater protective effect than men.
• Study used 65,800 vaccinated vs 263,200 controls, 3.4‑year follow‑up.
• Tdap comparison ruled out healthcare‑seeking confounding.
• Findings limited to insured, integrated‑care population.

Pulse Analysis

The recombinant zoster vaccine, marketed as Shingrix, has long been celebrated for its high efficacy in preventing shingles in adults over 50. Recent epidemiological work, however, suggests its benefits may extend far beyond dermatological protection. By leveraging electronic health records from a large integrated health system, researchers identified a striking 51% reduction in dementia diagnoses among vaccinated seniors, a signal that aligns with a growing body of literature linking viral immunity to brain health. This emerging perspective reframes vaccination as a potential component of broader age‑related disease prevention strategies.

Gender differences emerged as a notable feature of the analysis, with women experiencing a more pronounced decline in dementia risk than men. While the study did not pinpoint a biological mechanism, hypotheses include sex‑specific immune responses to varicella‑zoster reactivation and differential inflammatory pathways that influence neurodegeneration. If these hypotheses hold, targeted vaccination campaigns could yield disproportionate cognitive benefits for older women, a demographic already at heightened risk for Alzheimer’s disease. Public health planners may therefore consider gender‑aware messaging when promoting shingles immunization, especially in communities with low vaccine uptake.

Despite its promise, the research carries important caveats. The cohort comprised only insured individuals within a single health network, limiting extrapolation to broader, uninsured populations. Moreover, the average follow‑up of just over three years may undercapture the full trajectory of dementia, a disease that unfolds over decades. Future investigations should aim for longer observation periods, diverse demographic samples, and mechanistic studies to clarify how VZV immunity intersects with neuroinflammation. Until then, clinicians can cautiously view shingles vaccination as a low‑risk intervention with potential ancillary cognitive advantages, reinforcing its role in comprehensive geriatric care.

Women show greater dementia risk reduction from shingles vaccine

Denise Myshko · February 11, 2026

Key Takeaways

• Kaiser Permanente Southern California data (2018–2020) compared two‑dose recombinant zoster vaccine recipients with matched unvaccinated controls, excluding those with dementia diagnoses/medications within six months of dose two.

• Vaccination correlated with a 51 % lower incidence of dementia, with effect estimates stronger in women than men while remaining directionally consistent across demographic subgroups.

• Chart review augmented electronic coding to identify subsequent dementia and mild cognitive impairment, strengthening outcome ascertainment beyond claims‑based definitions alone.

• A negative‑control approach using Tdap‑vaccinated individuals (without shingles vaccination) still showed reduced dementia incidence, arguing against confounding by healthcare‑seeking or baseline health status.

• Limited generalizability (insured, integrated system) and relatively short follow‑up (mean 3.40 years; max 5.22 years) may underestimate cumulative dementia burden in a progressive disease course.

A new study finds that the recombinant zoster vaccine was associated with a 51 % lower risk of dementia. This was seen across age and racial and ethnic groups, but the risk reduction was stronger in women compared with men.

Another study is adding to the evidence that shingles vaccines are associated with a reduced risk of dementia. A real‑world study, published online as a manuscript on Feb. 9, 2026 in Nature Communications, has found women experienced a greater reduction of dementia from the recombinant zoster vaccine than men.

Shingles is a viral infection that occurs when the varicella‑zoster virus (VZV), the same virus that causes chickenpox, reactivates in the body. Although anyone can get shingles, it is more common in adults over the age of 50, according to the CDC. It presents as a rash, with painful blisters across the chest, abdomen, or face.

Shingrix is a recombinant zoster vaccine (RZV) that is manufactured by GSK, which funded the current research. It is indicated to prevent shingles in people who are 50 years of age and older and those over the age of 18 who are immunocompromised.

Researchers have speculated about the potential role of the varicella‑zoster virus in the development of dementia. The exact mechanism of how reactivation of the virus leads to the development of dementia is not known. One study, published in 2022, showed that neural stem cells infected with varicella‑zoster virus or herpes simplex virus type 1 show increased levels of pro‑inflammatory cytokines.

Research over the last few years has begun to shed light on the positive effect of the vaccines beyond preventing the development of shingles, including reducing all‑cause mortality and major adverse cardiovascular events (MACE) in adults over 50 and reducing mortality and MACE risks in people living with HIV. Additionally, studies of the live‑attenuated herpes zoster vaccine (Merck’s Zostavax) have shown delaying or preventing mild cognitive impairment and dementia.

In the Nature Communications study, researchers from Kaiser Permanente Southern California conducted a retrospective matched cohort study of adults aged 65 years and older who received two doses of the recombinant zoster vaccine compared with controls who did not receive the vaccine.

Researchers, led by Emily Rayens, Ph.D., MPH, a postdoctoral researcher in the department of research and evaluation at Kaiser Permanente Southern California, analyzed electronic health records between April 1, 2018, and Dec. 31, 2020, of people aged 65 and older who had no dementia diagnoses or dementia medications within six months of their second vaccine dose. The analysis included 65,800 vaccinated people and 263,200 people who were unvaccinated. Researchers also conducted chart reviews to identify those who were later diagnosed with dementia and mild cognitive impairment.

Researchers found that vaccination with two doses of the recombinant zoster vaccine was associated with a 51 % lower risk of dementia. This was seen across age and racial and ethnic groups, but the risk reduction was stronger in women compared with men.

Researchers also wanted to evaluate the potential bias that could result from healthy people who have been vaccinated. They assessed dementia incidence in those who had received a recombinant zoster vaccine compared with those who had received a tetanus, diphtheria, and acellular pertussis (Tdap) vaccine but not the shingles vaccine. In this analysis, vaccination for shingles also showed a significant reduction in dementia.

Researchers said one limitation is that the results may not be generalizable to other patient populations or to the uninsured. Additionally, assessment for dementia was conducted at a mean follow‑up of 3.40 years with a maximum follow‑up of 5.22 years. Because dementia is a progressive disease, researchers may not have seen the entirety of dementia cases during the study timeframe.

“While additional research is needed to understand the potential underlying mechanisms, these results suggest that there may be additional benefits to RZV [recombinant zoster vaccine] vaccination beyond prevention of HZ [herpes zoster],” the researchers wrote.